Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies

  • Evotec SE today announced that the Company has joined forces with the Crohn’s & Colitis Foundation (“the Foundation”), the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease (“IBD”), which includes Crohn’s disease and ulcerative colitis.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-crohns–colitis-foundation-enter-agreement-to-advance-drug-discovery-for-novel-ibd-therapies-6366

    Du magst vielleicht auch